Here we show in detail the cleavage of the pre-RC proteins Mcm3 and Cdc6 by caspase-3 and caspase-7, including characterization of the cleavage sites. Localization as well as binding properties of the protein fragments generated in apoptotic cells are discussed, and a reinforcing proapoptotic mechanism for one of the Mcm3 fragments is described.
After the induction of apoptosis in the Burkitt's lymphoma cell line BL60-2, HeLa cells or the T cell line H9 by various stimuli, MCM proteins and Cdc6 were analyzed by immunoblotting. Proteolytic cleavage of Mcm3 and Cdc6 was observed in all cases ( Figure 1a , upper and middle panel), while Mcm2 and Mcm4-7 remained unchanged (data not shown). The observed Mcm3 fragment has an apparent size of B90 kDa in agreement with previous reports. 7, 8 The main cleavage product of Cdc6 had an apparent size of B45 kDa with a second fragment of B35 kDa appearing later in the apoptotic process (Figure 1a , middle panel). In response to each apoptotic stimulus, cleavage of replication initiation proteins was accompanied by activated caspase-3, the main executioner caspase in apoptotic cells (Figure 1a , lower panel). Further in vitro analysis using recombinant proteins identified caspase-3 and caspase-7 as the proteases capable to cleave Mcm3 and Cdc6 (see supplementary information).
To identify the actual sites used for caspase cleavage, we performed site-directed mutagenesis of potential caspase recognition sites and assayed in vitro translated Cdc6 and Mcm3 protein fragments for proteolysis by recombinant caspase-3. For Mcm3, mutation of the aspartic acid corresponding to amino-acid 701 in the full-length protein to alanine resulted in the prevention of cleavage. A corresponding epitope tagged protein expressed in HeLa cells proved to be resistant to proteolysis (Figure 1b, In contrast, transfection of the full-length Mcm3 constructs (either wild type or caspase resistant) induced only a moderate increase of caspase activity in this highly sensitive assay when compared to mock-transfected cells. This finding indicates a reinforcing proapoptotic activity for the apoptotic, N-terminal Mcm3 fragment that might be involved in the sustaining of signaling cascades or even enhance the execution of apoptosis.
In analogy to our Mcm3 approach, we generated expression vectors coding for the N-and C-terminal Cdc6 fragments as well as the full-length protein and its caspase-resistant counterpart (see Figure 1e for an overview of Cdc6 versions). In immunofluorescence experiments, the intracellular localization of full-length Cdc6, its uncleavable version as well as of the N-terminal fragment was either nuclear (colocalization . Interestingly, both the N-and C-terminal fragments generated upon induction of apoptosis in HeLa cells transfected with the wild-type Cdc6 expression construct localized exclusively to the cytoplasm (see supplementary information). To further characterize the apoptotic Cdc6 fragments and the cleavageresistant Cdc6, we analyzed their capability to bind chromatin in comparison to wild-type Cdc6, when overexpressed in starved murine embryonal fibroblasts, which downregulate the endogenous Cdc6 protein. 10 All versions of the Cdc6 protein that were localized to the nucleus (see above) were able to bind to chromatin (Figure 1e ).
While this work was in progress, an additional caspase-3 cleavage site in the Cdc6 protein was reported at LVFD 99 . 11 We therefore tried to visualize the corresponding apoptotic Cdc6 fragment of B52 kDa described. The fragment was not detectable in apoptotic cell extracts with our anti-Cdc6 antibody, which binds in the N-terminal half of the protein. It was also not visible after generation of radiolabeled full-length Cdc6 in a coupled in vitro transcription/reticulocyte lysate translation system and subsequent cleavage of the protein with recombinant caspase-3, circumventing the use of antibodies. Only one large fragment of about 45 kDa was generated from wild-type Cdc6 (data not shown). In addition, we overexpressed in HeLa cells both wild-type Cdc6 and the caspase-resistant Cdc6 protein, each epitope tagged at both the N-and C-terminus. After induction of apoptosis, cell extracts were analyzed by immunoblots using the epitopedirected antibodies. Again, only the fragments observed before could be identified (see supplementary information). Using the experimental conditions in our study, this excludes apoptotic Cdc6 cleavage sites other than DEMD 287 and SEVD
442
. Taken together, we were able to show cleavage of the pre-RC components Mcm3 and Cdc6 in different cell lines in response to various apoptotic stimuli. Mechanistically, such a process could ensure the inhibition of DNA replication in dying cells, thus preserving ATP for the apoptotic processes. The latter is likely to be important as ATP depletion was shown to switch apoptotic to necrotic cell death with its known side effects. 3 Furthermore, we were able to show a reinforcing proapoptotic function for the large apoptotic Mcm3 fragment. Therefore, the cleavage of Mcm3 might have a function in apoptosis per se, exceeding the inhibition of DNA replication. Figure 1 (a) Mcm3 and Cdc6 are cleaved in response to various apoptotic stimuli. BL60-2 cells were cultured as described. 6 HeLa cells were cultured in Dulbecco's MEM with 10% FCS and 25 mg/ml gentamicin. H9 cells were cultured in RPMI-1640 with 10% FCS and gentamicin. Whole-cell protein extracts (SDS lysis) were prepared from BL60-2 cells, HeLa cells and H9 cells before and after induction of apoptosis with 1.3 mg/ml goat anti-human IgM F(ab) 2 antibody, 250 mM calcium ionophore A 23187, 120 mJ/cm 2 UV light, 1 mM staurosporine or 1 mg/ml anti-CD95 antibody followed by crosslinking F(ab) 2 
